David Tordrup
Research Subjects
David Tordrup has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
Panos Kanavos
London School of Economics
5 shared publications- Alessandro Desideri
Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy
4 shared publications - Birgitta Ruth Knudsen
Aarhus University
4 shared publications - Aris Angelis
Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK
3 shared publications - Aukje K. Mantel-Teeuwisse
Utrecht University
3 shared publications - Hendrika A. van Den Ham
Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 27 September 2023
- Published by Elsevier in Health Policy
- Vol. 138, 104919
A systematic review of policies regulating or removing mark-ups in the pharmaceutical supply and distribution chain
- 27 September 2023
- Published by Elsevier in Health Policy
- Vol. 138, 104919
Open AccessA systematic review of policies regulating or removing mark-ups in the pharmaceutical supply and distribution chain
- Open Access
- 7 November 2022
- Published by Elsevier in Health Policy
- Vol. 134, 104681
Evidence on the effectiveness of policies promoting price transparency - A systematic review
- 7 November 2022
- Published by Elsevier in Health Policy
- Vol. 134, 104681
Open AccessEvidence on the effectiveness of policies promoting price transparency - A systematic review
- Open Access
- 13 March 2022
- Published by Elsevier in Health Policy
- Vol. 134, 104576
A critical review of methodologies used in pharmaceutical pricing policy analyses
- 13 March 2022
- Published by Elsevier in Health Policy
- Vol. 134, 104576
Open AccessA critical review of methodologies used in pharmaceutical pricing policy analyses
- Open Access
- 1 January 2022
- Published by BMJ in BMJ Global Health
- Vol. 7 (2) , e004512
Economic burden of female genital mutilation in 27 high-prevalence countries
Background Female genital mutilation (FGM) is a traditional harmful practice affecting 200 million women and girls globally. Health complications of FGM occur immediately and over time, and are associated with healthcare costs that are poorly understood. Quantifying the global FGM-related burden is essential for supporting programmes and policies for prevention and mitigation. Methods Health complications of FGM are derived from a meta-analysis and stratified by acute, uro-gynaecological, obstetric and psychological/sexual. Treatment costs are calculated from national cohort models of 27 high-burden countries over 30 years. Savings associated with full/partial abandonment are compared with a current incidence reference scenario, assuming no changes in FGM practices. Results Our model projects an increasing burden of FGM due to population growth. As a reference scenario assuming no change in practices, prevalent cases in 27 countries will rise from 119.4 million (2018) to 205.8 million (2047). Full abandonment could reduce this to 80.0 million (2047), while partial abandonment is insufficient to reduce cases. Current incidence economic burden is US$1.4 billion/year, rising to US$2.1 billion/year in 2047. Full abandonment would reduce the future burden to US$0.8 billion/year by 2047. Conclusion FGM is a human rights violation, a public health issue and a substantial economic burden that can be avoided through effective prevention strategies. While decreasing trends are observed in some countries, these trends are variable and not consistently observed across settings. Additional resources are needed to prevent FGM to avoid human suffering and growing costs. The findings of this study warrant increased political commitment and investment in the abandonment of FGM.
- 1 January 2022
- Published by BMJ in BMJ Global Health
- Vol. 7 (2) , e004512
Open AccessEconomic burden of female genital mutilation in 27 high-prevalence countries
Background Female genital mutilation (FGM) is a traditional harmful practice affecting 200 million women and girls globally. Health complications of FGM occur immediately and over time, and are associated with healthcare costs that are poorly understood. Quantifying the global FGM-related burden is essential for supporting programmes and policies for prevention and mitigation. Methods Health complications of FGM are derived from a meta-analysis and stratified by acute, uro-gynaecological, obstetric and psychological/sexual. Treatment costs are calculated from national cohort models of 27 high-burden countries over 30 years. Savings associated with full/partial abandonment are compared with a current incidence reference scenario, assuming no changes in FGM practices. Results Our model projects an increasing burden of FGM due to population growth. As a reference scenario assuming no change in practices, prevalent cases in 27 countries will rise from 119.4 million (2018) to 205.8 million (2047). Full abandonment could reduce this to 80.0 million (2047), while partial abandonment is insufficient to reduce cases. Current incidence economic burden is US$1.4 billion/year, rising to US$2.1 billion/year in 2047. Full abandonment would reduce the future burden to US$0.8 billion/year by 2047. Conclusion FGM is a human rights violation, a public health issue and a substantial economic burden that can be avoided through effective prevention strategies. While decreasing trends are observed in some countries, these trends are variable and not consistently observed across settings. Additional resources are needed to prevent FGM to avoid human suffering and growing costs. The findings of this study warrant increased political commitment and investment in the abandonment of FGM.
- Open Access
- 29 December 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Public-private partnerships and collaboration in digital health: a scoping review and case study analysis of applications during the COVID-19 pandemic (Preprint)
BACKGROUND The emergence of digital technologies over the past decade has presented a novel opportunity to address healthcare challenges associated with COVID-19 and accelerate progress towards achieving the health-related goals under the 2030 Sustainable Development Agenda. Public-private partnerships (PPPs) have played a vital role in scaling up digital health solutions and disseminating curated scientific information in the face of the infodemic. However, several challenges remain around the effectiveness of PPP-related digital solutions and antagonistic viewpoints of engaging the private sector. We sought to evaluate the role of public-private partnerships in the digital public health space during COVID-19 and identify key lessons learned and challenges in the uptake of digital health solutions globally. OBJECTIVE Electronic and grey literature search results from PubMed, Google, and Google Scholar were screened by one reviewer through a two-stage process. We included all relevant systematic reviews, interventional, observational, and descriptive studies published in English published from January 2020 to June 2021. Two case study analyses on digital health chatbots, informed by expert opinion, were also performed to assess for the role of public-private partnerships in advancing digital public health solutions. METHODS Electronic and grey literature search results from PubMed, Google, and Google Scholar were screened by one reviewer through a two-stage process. We included all relevant systematic reviews, interventional, observational, and descriptive studies published in English published from January 2020 to June 2021. Two case study analyses on digital health chatbots, informed by expert opinion, were also performed to assess for the role of public-private partnerships in advancing digital public health solutions. RESULTS Forty-five articles met the inclusion criteria for qualitative analysis, the majority of which were secondary research. Results of the publications can be broadly categorized into three groups: (1) models and definitions of public-private partnerships used in the healthcare space; (2) purposes of and motivations of public-private partnerships in global public health; and (3) and facilitators, barriers, and challenges to date. CONCLUSIONS The literature review as well as the case studies analysis reveal that PPPs can represent a valid option for tackling global healthcare issues with a digital health approach. Further research is needed to complement the initial findings of the present paper, as well as to assess a wider pool of case studies and the different features that they might present.
- 29 December 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPublic-private partnerships and collaboration in digital health: a scoping review and case study analysis of applications during the COVID-19 pandemic (Preprint)
BACKGROUND The emergence of digital technologies over the past decade has presented a novel opportunity to address healthcare challenges associated with COVID-19 and accelerate progress towards achieving the health-related goals under the 2030 Sustainable Development Agenda. Public-private partnerships (PPPs) have played a vital role in scaling up digital health solutions and disseminating curated scientific information in the face of the infodemic. However, several challenges remain around the effectiveness of PPP-related digital solutions and antagonistic viewpoints of engaging the private sector. We sought to evaluate the role of public-private partnerships in the digital public health space during COVID-19 and identify key lessons learned and challenges in the uptake of digital health solutions globally. OBJECTIVE Electronic and grey literature search results from PubMed, Google, and Google Scholar were screened by one reviewer through a two-stage process. We included all relevant systematic reviews, interventional, observational, and descriptive studies published in English published from January 2020 to June 2021. Two case study analyses on digital health chatbots, informed by expert opinion, were also performed to assess for the role of public-private partnerships in advancing digital public health solutions. METHODS Electronic and grey literature search results from PubMed, Google, and Google Scholar were screened by one reviewer through a two-stage process. We included all relevant systematic reviews, interventional, observational, and descriptive studies published in English published from January 2020 to June 2021. Two case study analyses on digital health chatbots, informed by expert opinion, were also performed to assess for the role of public-private partnerships in advancing digital public health solutions. RESULTS Forty-five articles met the inclusion criteria for qualitative analysis, the majority of which were secondary research. Results of the publications can be broadly categorized into three groups: (1) models and definitions of public-private partnerships used in the healthcare space; (2) purposes of and motivations of public-private partnerships in global public health; and (3) and facilitators, barriers, and challenges to date. CONCLUSIONS The literature review as well as the case studies analysis reveal that PPPs can represent a valid option for tackling global healthcare issues with a digital health approach. Further research is needed to complement the initial findings of the present paper, as well as to assess a wider pool of case studies and the different features that they might present.
- Open Access
- 14 December 2021
- Published by Elsevier in The Lancet Global Health
- Vol. 10 (1) , e52-e62
Global return on investment and cost-effectiveness of WHO's HEAR interventions for hearing loss: a modelling study
- 14 December 2021
- Published by Elsevier in The Lancet Global Health
- Vol. 10 (1) , e52-e62
Open AccessGlobal return on investment and cost-effectiveness of WHO's HEAR interventions for hearing loss: a modelling study
- Open Access
- 1 December 2020
- Published by Elsevier in Value in Health
- Vol. 23 (12) , 1552-1560
Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income
- 1 December 2020
- Published by Elsevier in Value in Health
- Vol. 23 (12) , 1552-1560
Open AccessCost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income
- Open Access
- 1 September 2019
- Published by Elsevier in The Lancet Global Health
- Vol. 7 (9) , e1180-e1188
Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30
- 1 September 2019
- Published by Elsevier in The Lancet Global Health
- Vol. 7 (9) , e1180-e1188
Open AccessAdditional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30
- Open Access
- 13 June 2019
- Published by Springer Nature in BMC Health Services Research
- Vol. 19 (1) , 1-12
Evaluating medicine prices, availability and affordability in Bangladesh using World Health Organisation and Health Action International methodology
Previous studies have shown limited availability of medicines in health facilities in Bangladesh. While medicines are dispensed for free in public facilities, they are paid out-of-pocket in private pharmacies. Availability, price and affordability are key concerns for access to medicines in Bangladesh. The World Health Organization/Health Action International survey methodology was used to determine price, availability and affordability of 61 lowest price generic (LPG) and originator branded medicines in public facilities, private retail pharmacies and private clinics across 6 regions of Bangladesh. Medicines for non-communicable and infectious diseases, and both on and off the national Essential Medicines List were included. Prices were compared internationally using Median Price Ratio (MPR). Mean LPG (originator brand) availability in the public sector, private retail pharmacies, and private clinics was 37%, 63 (4) percent, and 54 (2) percent, respectively. Medicines for Non-Communicable Diseases (NCD) and essential medicines were significantly less available than infectious disease medicines and non-essential medicines, respectively. Mean LPG (originator brand) MPR was 0.977 in the public sector, 1.700 (3.698) in private retail pharmacies and 1.740 (3.758) in private clinics. Six medicines were expensive by international standards across all sectors. The least affordable treatments in both private sectors were bisoprolol (hypertension), metformin (diabetes) and atorvastatin (hypercholesterolemia). Availability and affordability of NCD medicines are key concerns where the burden of NCD is rising. These findings show improvement from earlier studies, but room for further advances in availability and affordability of NCD medicines in Bangladesh. A small number of medicines are consistently expensive across sectors in Bangladesh, suggesting the need for strategies to address prices for certain medicines.
- 13 June 2019
- Published by Springer Nature in BMC Health Services Research
- Vol. 19 (1) , 1-12
Open AccessEvaluating medicine prices, availability and affordability in Bangladesh using World Health Organisation and Health Action International methodology
Previous studies have shown limited availability of medicines in health facilities in Bangladesh. While medicines are dispensed for free in public facilities, they are paid out-of-pocket in private pharmacies. Availability, price and affordability are key concerns for access to medicines in Bangladesh. The World Health Organization/Health Action International survey methodology was used to determine price, availability and affordability of 61 lowest price generic (LPG) and originator branded medicines in public facilities, private retail pharmacies and private clinics across 6 regions of Bangladesh. Medicines for non-communicable and infectious diseases, and both on and off the national Essential Medicines List were included. Prices were compared internationally using Median Price Ratio (MPR). Mean LPG (originator brand) availability in the public sector, private retail pharmacies, and private clinics was 37%, 63 (4) percent, and 54 (2) percent, respectively. Medicines for Non-Communicable Diseases (NCD) and essential medicines were significantly less available than infectious disease medicines and non-essential medicines, respectively. Mean LPG (originator brand) MPR was 0.977 in the public sector, 1.700 (3.698) in private retail pharmacies and 1.740 (3.758) in private clinics. Six medicines were expensive by international standards across all sectors. The least affordable treatments in both private sectors were bisoprolol (hypertension), metformin (diabetes) and atorvastatin (hypercholesterolemia). Availability and affordability of NCD medicines are key concerns where the burden of NCD is rising. These findings show improvement from earlier studies, but room for further advances in availability and affordability of NCD medicines in Bangladesh. A small number of medicines are consistently expensive across sectors in Bangladesh, suggesting the need for strategies to address prices for certain medicines.
- Open Access
- 30 October 2017
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 33 (6) , 609-619
PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION
Background:The importance of economic evaluation in decision making is growing with increasing budgetary pressures on health systems. Diverse economic evidence is available for a range of interventions across national contexts within Europe, but little attention has been given to identifying evidence gaps that, if filled, could contribute to more efficient allocation of resources. One objective of the Research Agenda for Health Economic Evaluation project is to determine the most important methodological evidence gaps for the ten highest burden conditions in the European Union (EU), and to suggest ways of filling these gaps.Methods:The highest burden conditions in the EU by Disability Adjusted Life Years were determined using the Global Burden of Disease study. Clinical interventions were identified for each condition based on published guidelines, and economic evaluations indexed in MEDLINE were mapped to each intervention. A panel of public health and health economics experts discussed the evidence during a workshop and identified evidence gaps.Results:The literature analysis contributed to identifying cross-cutting methodological and technical issues, which were considered by the expert panel to derive methodological research priorities.Conclusions:The panel suggests a research agenda for health economics which incorporates the use of real-world evidence in the assessment of new and existing interventions; increased understanding of cost-effectiveness according to patient characteristics beyond the “-omics” approach to inform both investment and disinvestment decisions; methods for assessment of complex interventions; improved cross-talk between economic evaluations from health and other sectors; early health technology assessment; and standardized, transferable approaches to economic modeling.
- 30 October 2017
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 33 (6) , 609-619
Open AccessPRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION
Background:The importance of economic evaluation in decision making is growing with increasing budgetary pressures on health systems. Diverse economic evidence is available for a range of interventions across national contexts within Europe, but little attention has been given to identifying evidence gaps that, if filled, could contribute to more efficient allocation of resources. One objective of the Research Agenda for Health Economic Evaluation project is to determine the most important methodological evidence gaps for the ten highest burden conditions in the European Union (EU), and to suggest ways of filling these gaps.Methods:The highest burden conditions in the EU by Disability Adjusted Life Years were determined using the Global Burden of Disease study. Clinical interventions were identified for each condition based on published guidelines, and economic evaluations indexed in MEDLINE were mapped to each intervention. A panel of public health and health economics experts discussed the evidence during a workshop and identified evidence gaps.Results:The literature analysis contributed to identifying cross-cutting methodological and technical issues, which were considered by the expert panel to derive methodological research priorities.Conclusions:The panel suggests a research agenda for health economics which incorporates the use of real-world evidence in the assessment of new and existing interventions; increased understanding of cost-effectiveness according to patient characteristics beyond the “-omics” approach to inform both investment and disinvestment decisions; methods for assessment of complex interventions; improved cross-talk between economic evaluations from health and other sectors; early health technology assessment; and standardized, transferable approaches to economic modeling.